Articles tagged with Heparin
A new technology uses microparticles of heparin to bind and deliver the potent protein BMP-2, reducing unwanted bone formation and increasing efficiency. The study found that the microparticles maintained high bioactivity and released growth factor slowly over time.
A study comparing heparin and bivalirudin found that patients treated with heparin had significantly fewer major cardiovascular events at 28 days compared to those receiving bivalirudin. Heparin was also shown to reduce repeat heart attacks caused by stent thrombosis.
Researchers found that heparin interactions with the terminal domains of murine prion protein stabilize the protein, preventing aggregation. This stabilization prevents prion conversion and disease. Heparin may establish groundwork for therapeutic use against prion diseases.
Researchers created a synthetic version of low-molecular-weight heparin that can be counteracted by an existing drug and cleared by the liver, not the kidneys. This new form of heparin is safer for patients with poor kidney function, reducing the risk of uncontrolled bleeding.
A team led by Robert Linhardt and Jian Liu created a synthetic form of low-molecular-weight heparin, which can be reversed in cases of overdose and is safer for patients with poor kidney function. The new drug is also cost-effective and has improved properties compared to the animal-derived alternative.
Researchers developed chemical agents that bind and potentially remove the anti-coagulant heparin, improving patient care. The system is biodegradable, reducing the risk of side effects.
The EUROMAX trial reveals that administering bivalirudin to STEMI patients in pre-hospital settings significantly reduces death and major bleeding complications compared to heparin. Bivalirudin also showed a lower rate of reinfarction and death, however with increased risk of acute stent thrombosis.
Researchers found that basic fibroblast growth factor and heparin promote differentiation of MSCs into motor neurons, increasing acetylcholine levels. This technology may prevent and treat muscular atrophy caused by peripheral nerve injury.
A large observational study questions whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality rates. The study found no evidence that treatment with bivalirudin improves outcome compared to heparin alone.
A new study found that patients who underwent cardiac device surgery without interrupting warfarin treatment had a 80% lower risk of developing significant hematomas compared to those bridged with heparin. This approach also reduced prolonged hospital stays, re-interruption of anticoagulation, and re-operations.
The study found that a single dose of tenecteplase reduced incidence of circulatory system collapse by 56% in patients with submassive or intermediate-risk pulmonary embolism. Patients under 75 years old had the most benefit and fewer hemorrhagic strokes.
Researchers at the University of York have developed a new dye, 'Mallard Blue', which can rapidly detect heparin levels in human serum. The dye has excellent sensing capacity for heparin and may improve upon existing clinical methods.
Researchers investigate using heparin to optimize therapeutic delivery with ultrasound into the brain, increasing treatment efficacy for CNS diseases. Initial results show promising potential in enhancing drug permeability and reducing side effects.
Researchers say anti-clotting effect of heparin is well established but its impact on cancer patients remains unclear. The SAVE-ONCO study found semuloparin reduced thromboembolism incidence but had no significant effect on major bleeding and death.
Researchers developed a simple color test to detect economically motivated adulterants (EMAs) in heparin, which can trigger anaphylactic reactions. The test can also identify other potential EMAs, paving the way for portable detection methods.
A Pew Charitable Trusts study reveals serious gaps in US drug safety oversight, with 40% of finished drugs sourced from overseas. The report identifies links in the supply chain that need strengthening to ensure safe medicines.
Researchers found that women with recurrent miscarriage have a cumulative incidence of natural conception of 56% after six months, 74% after 12 months, and 86% after 24 months. The median time to a subsequent pregnancy was 21 weeks, regardless of outcome.
Researchers identified heparin as the underlying mechanism that initiates the production of bradykinin, contributing to swelling, anaphylactic, and inflammatory symptoms associated with aberrant mast cell activity. This discovery provides a new strategy for treating allergic diseases by blocking bradykinin or factor XII activity.
Scientists developed a new medical imaging agent using firefly luciferase that emits near-infrared light, successfully detecting factor Xa proteins in laboratory experiments. The discovery offers promise for improved monitoring of heparin therapy and treatment of blood clots.
A Scripps Research scientist has identified a natural molecule that inhibits the activation of thrombin-activatable fibrinolysis inhibitor (TAFI), preventing stable clot formation. This discovery could lead to novel and cost-effective treatments for blood clotting diseases like Hemophilia A.
Scientists developed a firefly protein that emits near-infrared light, successfully detecting minute amounts of factor Xa in laboratory experiments. The advance offers promise for improved monitoring of heparin therapy, a treatment for blood clots.
A recent study published in JAMA found that using lower doses of heparin during coronary procedures does not significantly reduce the risk of major bleeding. The research involved 2,026 patients and compared two dose regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients.
A recent study found that ultra-low-molecular-weight heparin semuloparin reduces the incidence of venous thromboembolism (VTE) and all-cause death by 25% in orthopedic surgery patients compared to enoxaparin.
A CDC investigation found that contaminated pre-filled heparin and saline syringes from a single company led to 162 S. marcescens bloodstream infections in nine states. The company failed to comply with FDA's Good Manufacturing Practices, leading to the voluntary recall of affected syringes.
A study of 320 patients found heparin-induced skin lesions in 7.5% of cases, mostly due to delayed-type hypersensitivity response. Pregnancy, obesity, and long treatment duration increased the risk of such reactions.
The HORIZONS-AMI trial demonstrates that drug-eluting stents are safer and more effective than bare-metal stents for heart attack patients. Bivalirudin anticoagulation enhances safety and efficacy compared to heparin + GPIIb/IIIa inhibitors.
The HORIZONS-AMI trial showed that bivalirudin therapy significantly reduces major bleeding and cardiac death in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending (LAD) artery. In high-risk STEMI patients, bivalirudin also provides the greatest mortality benefit.
The HORIZONS-AMI study found that bivalirudin reduced clinical events and major bleeding in heart attack patients undergoing angioplasty. This is a significant finding with important clinical implications for the selection of treatment strategies for high-risk patients.
A phase II trial shows otamixaban, an intravenous blood clot inhibitor, reduces major coronary complications in high-risk ACS patients with lower bleeding rates compared to heparin. The study found intermediate doses of otamixaban offer a significant reduction in death and ischemic complications.
A new study published in The Lancet found that otamixaban significantly reduces the risk of death and second heart attacks in patients with non-ST-elevation acute coronary syndromes. The drug, which inhibits factor Xa, shows promise as an alternative to current standard treatments.
Researchers developed a lab-on-a-chip device mimicking the natural Golgi apparatus, producing heparin quickly and efficiently in an assembly-line fashion. The artificial Golgi has strong clot-fighting potential, potentially leading to faster and safer heparin production methods.
University of Michigan researchers have developed a simple method for detecting contaminants in heparin, a blood-thinning drug used to prevent and treat blood clots. The new method uses potentiometric polyanion sensors to distinguish pure heparin from tainted heparin containing oversulfated chondroitin sulfate.
The European Society of Cardiology recommends pre-hospital treatment with antiplatelet agents, such as aspirin and clopidogrel, to improve clinical outcomes in STEMI patients. Unfractionated heparin is also used during primary PCI in STEMI, while bivalirudin has been shown to reduce major bleeding and ischemic events.
Researchers at Rensselaer Polytechnic Institute have developed a fully synthetic heparin alternative that is safer and more pure than traditional heparin. The new version uses a process called chemoenzymatic synthesis to replicate the natural biosynthesis of heparin, resulting in a higher dose and lower risk of contamination.
Researchers have made a breakthrough in developing a safer, fully-synthetic version of heparin, a widely used blood thinner currently produced from pig intestines. The new synthesis method uses powerful enzymes to produce the pure heparin polymer, boosting production a million times higher than previous methods.
A study examining anti-clotting therapy following cardioembolic stroke found that warfarin treatment appears to be safe and can begin at any point during hospital stay. In contrast, bridging with full doses of heparin or enoxaparin may carry high risk of intracranial and systemic bleeding.
A team of researchers led by Rensselaer Polytechnic Institute's Robert J. Linhardt uncovered the source of deadly heparin contamination, a complex carbohydrate named oversulfated chondroitin sulfate. They are now developing stronger monitoring systems and exploring synthetic alternatives to ensure patient safety.
A contaminant in heparin, oversulfated chondroitin sulfate, was detected using advanced analytical techniques. The presence of this contaminant can trigger an allergy-like reaction, leading to severe symptoms like low blood pressure and abdominal pain.
Researchers found that mice treated with low-molecular weight heparin before or after vein damage healed faster than those not treated. The study's findings support the use of heparin as a preventative measure for deep-vein thrombosis, which affects millions of Americans each year.
Researchers have developed a new therapy for protein-losing enteropathy (PLE), a devastating condition that affects children after Fontan surgery. The treatment uses a heparin analog that prevents protein leakage without causing severe side effects, offering a safer alternative to current treatments.
A study of over 13,000 patients found that bivalirudin alone and other regimens have comparable mortality and ischemic outcomes at 1 year. Bivalirudin monotherapy reduces bleeding complications and hospital costs, making it a favored treatment option
The UNC School of Pharmacy team has developed a new synthetic form of heparin called Recomparin, which is less complex and easier to produce than previous forms. This reduction in structural complexity is expected to lower the risk of uncontrolled bleeding while maintaining the drug's anticoagulant properties.
A meta-analysis of previous studies finds that both unfractionated and low-molecular-weight heparin are effective in preventing blood clots in hospitalized patients. Venous thromboembolism is a major cause of complications and death, with most cases occurring outside the hospital.
A recent study published in The Lancet found that enoxaparin was 43% more effective at preventing venous thromboembolisms (VTEs) than unfractionated heparin. This result was consistent regardless of the severity of the stroke.
A new study found bivalirudin, an anti-clotting agent, is equally effective as a combination of injectable blood thinners in treating acute coronary syndromes, resulting in fewer cases of major bleeding. The medication reduced the risk of mortality by reducing bleeding complications.
A randomized trial shows that subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin in treating venous thromboembolism. The study found comparable rates of recurrent thromboembolism and major bleeding between the two groups.
A study led by McMaster University found that subcutaneous injections of unfractionated heparin can work as well as low-molecular weight heparin in treating venous thromboembolism, reducing hospitalization costs. This new treatment approach allows for outpatient care and may save patients up to $675 compared to traditional treatments.
Researchers at Rensselaer Polytechnic Institute have developed blood-compatible nanoscale materials using heparin composites or coatings. The composite heparin membrane with nanopores can filter blood and maintain its flow, potentially eliminating the need for systemic administration of heparin during kidney dialysis.
Researchers found that enoxaparin reduced the combined risk of death and MI within 30 days by 17 percent. Enoxaparin also reduced the 30-day risk of nonfatal repeat MI by 33 percent.
A multi-hospital project led by the University of Michigan Cardiovascular Center improved angioplasty care, increasing preventive medication use, reducing heparin and dye, and lowering complication rates. The study found a strong association between quality improvement efforts and patient outcomes.
Researchers at Rensselaer Polytechnic Institute have successfully synthesized hundreds of milligrams of heparin using engineered enzymes and co-factor recycling. This breakthrough could enable the widespread use of synthetic heparin in human medical treatments, reducing reliance on animal-derived products.
Researchers found a nearly twofold greater risk of death or hospitalization extending longer than 10 days for patients with heparin antibodies before surgery. The study also showed that patients with the antibodies fared worse than those without, regardless of their predicted surgical risk.
A study analyzing follow-up data from the SYNERGY trial found that enoxaparin and unfractionated heparin had similar death or nonfatal MI rates at six months, but mortality at one year was similar. Patients with high-risk ACS features remain at risk for continued adverse cardiac morbidity and mortality.
A recent study by Mayo Clinic researchers found that patients with high levels of heparin antibodies during hemodialysis have higher rates of adverse outcomes. The study suggests that detecting these antibodies may help identify patients at risk for complications, leading to potential improvements in treatment.
The meta-analysis of 22,000 patients found that enoxaparin was more effective than unfractionated heparin in preventing combined rates of death or heart attack. However, the difference was not significant for major bleeding or transfusion rates.
Studies show that enoxaparin is non-inferior to unfractionated heparin in preventing death or non-fatal myocardial infarction in patients with non-ST elevation acute coronary syndromes. Enoxaparin also shows a lower rate of non-fatal MI with a modest excess of bleeding.
A recent study found that patients with deep vein thrombosis (DVT) often did not receive prophylactic therapy in the 30-day period prior to their diagnosis. The researchers also noted that physicians frequently prescribed older treatment methods instead of evidence-based drugs, such as low molecular weight heparin.
A new analysis of over 10,000 patients with unstable angina or non-ST-segment elevation myocardial infarction found that the newer low molecular weight heparin enoxaparin improved outcomes compared to unfractionated heparin. The study also showed a reduced risk of death or non-fatal heart attack in patients treated with LMWH.
Researchers found a significant association between drops in blood pressure and mortality in patients who received protamine after bypass surgery. The study, conducted at Duke University Medical Center, suggests that even small blood pressure changes may be associated with increased risk of complications.
Dr. Linhardt developed low-molecular-weight heparins, a type of anticoagulant that can be administered as daily shots, reducing hospital costs and improving patient outcomes. His research also aims to manufacture the drug in labs rather than harvesting it from animal tissue.